The NOD-Like Receptor NLRP12 Attenuates Colon Inflammation and Tumorigenesis

Cancer Cell

Volumn 20, Issue 5, 2011, Pages 649-660

  Zaki, Md  Hasan ^a   Vogel, Peter ^a   Malireddi, R K Subbarao ^a   Body Malapel, Mathilde ^b   Anand, Paras K ^a   Bertin, John ^c   Green, Douglas R ^a   Lamkanfi, Mohamed ^d,e   Kanneganti, Thirumala Devi ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITÉ DE LILLE   (France)

^c GLAXOSMITHKLINE   (United States)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CRYOPYRIN; CYTOKINE; PROTEIN NLRP 12; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; COLITIS; COLORECTAL CARCINOMA; COLORECTAL TUMOR; CONTROLLED STUDY; HOMEOSTASIS; INTESTINE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL;

MUS;

EID: 81255189478     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.10.022     Document Type: Article

References (51)

1. Arthur J.C., Lich J.D., Aziz R.K., Kotb M., Ting J.P. Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kappaB-inducing kinase. J. Immunol. 2007, 179:6291-6296.
2. Arthur J.C., Lich J.D., Ye Z., Allen I.C., Gris D., Wilson J.E., Schneider M., Roney K.E., O'Connor B.P., Moore C.B., et al. Cutting edge: NLRP12 controls dendritic and myeloid cell migration to affect contact hypersensitivity. J. Immunol. 2010, 185:4515-4519.
3. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
4. Borghini S., Tassi S., Chiesa S., Caroli F., Carta S., Caorsi R., Fiore M., Delfino L., Lasiglie D., Ferraris C., et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of a NLRP12 mutation. Arthritis Rheum. 2011, 63:830-839.
5. Buchanan F.G., DuBois R.N. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006, 9:6-8.
6. Chen J.J., Lin Y.C., Yao P.L., Yuan A., Chen H.Y., Shun C.T., Tsai M.F., Chen C.H., Yang P.C. Tumor-associated macrophages: the double-edged sword in cancer progression. J. Clin. Oncol. 2005, 23:953-964.
7. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
8. Ekbom A., Helmick C., Zack M., Adami H.O. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 1990, 323:1228-1233.
9. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
10. Garlanda C., Riva F., Polentarutti N., Buracchi C., Sironi M., De Bortoli M., Muzio M., Bergottini R., Scanziani E., Vecchi A., et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc. Natl. Acad. Sci. USA 2004, 101:3522-3526.
11. González-Navajas J.M., Law J., Nguyen K.P., Bhargava M., Corr M.P., Varki N., Eckmann L., Hoffman H.M., Lee J., Raz E. Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production. J. Exp. Med. 2010, 207:2799-2807.
12. Goyette P., Labbé C., Trinh T.T., Xavier R.J., Rioux J.D. Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine. Ann. Med. 2007, 39:177-199.
13. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
14. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
15. Hill D.A., Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu. Rev. Immunol. 2010, 28:623-667.
16. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cézard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
17. Inohara, Chamaillard, McDonald C., Nuñez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 2005, 74:355-383.
18. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G7-G17.
19. Jéru I., Duquesnoy P., Fernandes-Alnemri T., Cochet E., Yu J.W., Lackmy-Port-Lis M., Grimprel E., Landman-Parker J., Hentgen V., Marlin S., et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc. Natl. Acad. Sci. USA 2008, 105:1614-1619.
20. Jéru I., Marlin S., Le Borgne G., Cochet E., Normand S., Duquesnoy P., Dastot-Le Moal F., Cuisset L., Hentgen V., Fernandes Alnemri T., et al. Functional consequences of a germline mutation in the leucine-rich repeat domain of NLRP3 identified in an atypical autoinflammatory disorder. Arthritis Rheum. 2010, 62:1176-1185.
21. Kanneganti T.D., Lamkanfi M., Núñez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007, 27:549-559.
22. Kanneganti T.D., Ozören N., Body-Malapel M., Amer A., Park J.H., Franchi L., Whitfield J., Barchet W., Colonna M., Vandenabeele P., et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006, 440:233-236.
23. Kawai T., Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. 2007, 13:460-469.
24. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008, 118:3367-3377.
25. Lech M., Avila-Ferrufino A., Skuginna V., Susanti H.E., Anders H.J. Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int. Immunol. 2010, 22:717-728.
26. Lee E.G., Boone D.L., Chai S., Libby S.L., Chien M., Lodolce J.P., Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289:2350-2354.
27. Lee S.H., Hu L.L., Gonzalez-Navajas J., Seo G.S., Shen C., Brick J., Herdman S., Varki N., Corr M., Lee J., Raz E. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat. Med. 2010, 16:665-670.
28. Leu C.M., Wong F.H., Chang C., Huang S.F., Hu C.P. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003, 22:7809-7818.
29. Lich J.D., Williams K.L., Moore C.B., Arthur J.C., Davis B.K., Taxman D.J., Ting J.P. Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes. J. Immunol. 2007, 178:1256-1260.
30. Liew F.Y., Xu D., Brint E.K., O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 2005, 5:446-458.
31. Luo J.L., Maeda S., Hsu L.C., Yagita H., Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004, 6:297-305.
32. Macaluso F., Nothnagel M., Parwez Q., Petrasch-Parwez E., Bechara F.G., Epplen J.T., Hoffjan S. Polymorphisms in NACHT-LRR (NLR) genes in atopic dermatitis. Exp. Dermatol. 2007, 16:692-698.
33. Maeda S., Hsu L.C., Liu H., Bankston L.A., Iimura M., Kagnoff M.F., Eckmann L., Karin M. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005, 307:734-738.
34. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
35. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
36. Miceli-Richard C., Lesage S., Rybojad M., Prieur A.M., Manouvrier-Hanu S., Häfner R., Chamaillard M., Zouali H., Thomas G., Hugot J.P. CARD15 mutations in Blau syndrome. Nat. Genet. 2001, 29:19-20.
37. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
38. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
39. Schoultz I., Verma D., Halfvarsson J., Törkvist L., Fredrikson M., Sjöqvist U., Lördal M., Tysk C., Lerm M., Söderkvist P., Söderholm J.D. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am. J. Gastroenterol. 2009, 104:1180-1188.
40. Shiff S.J., Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J. Exp. Med. 1999, 190:445-450.
41. Terzic J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114.
42. van Vliet C., Bukczynska P.E., Puryer M.A., Sadek C.M., Shields B.J., Tremblay M.L., Tiganis T. Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase. Nat. Immunol. 2005, 6:253-260.
43. Vereecke L., Sze M., McGuire C., Rogiers B., Chu Y., Schmidt-Supprian M., Pasparakis M., Beyaert R., van Loo G. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp. Med. 2010, 207:1513-1523.
44. Villani A.C., Lemire M., Fortin G., Louis E., Silverberg M.S., Collette C., Baba N., Libioulle C., Belaiche J., Bitton A., et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat. Genet. 2009, 41:71-76.
45. Wang L., Manji G.A., Grenier J.M., Al-Garawi A., Merriam S., Lora J.M., Geddes B.J., Briskin M., DiStefano P.S., Bertin J. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. J. Biol. Chem. 2002, 277:29874-29880.
46. Wilkins J.A., Sansom O.J. C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer Res. 2008, 68:4963-4966.
47. Williams K.L., Lich J.D., Duncan J.A., Reed W., Rallabhandi P., Moore C., Kurtz S., Coffield V.M., Accavitti-Loper M.A., Su L., et al. The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J. Biol. Chem. 2005, 280:39914-39924.
48. Xiao H., Yin W., Khan M.A., Gulen M.F., Zhou H., Sham H.P., Jacobson K., Vallance B.A., Li X. Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology 2010, 139:574-585.
49. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
50. Zaki M.H., Lamkanfi M., Kanneganti T.D. The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol. 2011, 32:171-179.
51. Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T.D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32:379-391.